Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025

Reuters

Sep 04

Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025

Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2564822375"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564822375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564822375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564822375","market":"us","top_or_hot":-1,"title":"Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL7QLRpT:1","article_id":"2564822375","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564822375","pubTimestamp":1756981848,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis  in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium , an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMUX":"Immunic, Inc."},"translate_title":"Immunic Inc.在ECTRIMS 2025上宣布维多氟地莫斯钙治疗进行性多发性硬化症的新临床研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":0.9},"content_text":"Immunic Inc. Announces New Clinical Study Results on Vidofludimus Calcium for Progressive Multiple Sclerosis at ECTRIMS 2025\n    \n\n        Immunic Inc., a biotechnology company specializing in the development of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, from September 24-26, 2025. During this conference, Immunic will present data on its lead asset, vidofludimus calcium (IMU-838), an orally available Nurr1 activator. The data will be shared through an oral presentation and four poster presentations, including a late-breaking poster. These presentations will cover analyses from the Phase 2 EMPhASIS Study of vidofludimus calcium in patients with Relapsing-Remitting Multiple Sclerosis. The presentation and posters will be made accessible on Immunic's website. Results from these studies will be presented during the specified conference sessions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2191562_en), on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}